Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Other changes at Pfizer include Mikael Dolsten ... He will also cover business analytics, global commercial operations and patient and health impact, among others. Pfizer’s Consumer Healthcare ...

This caused Pfizer to change its tactics ... a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word. This era, though, was also marked ...

(Reuters) -Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, highlighting its operational efficiency even as it ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

And the key policy change impacts on Pfizer was a reduced ability to raise ... opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again ...